Design and Synthesis of HIF-1 Inhibitors as Anti-Cancer Therapeutics
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Hypoxia, or reduced of oxygen pressure, in healthy cells leads to cell necrosis and reoxygenation
injuries; however, hypoxia is a prominent property of most solid tumors. The low oxygen
pressure in cells activates the hypoxia-inducible factor (HIF) family of transcription factors,
which induce targets genes that regulates adaptive biological processes such as anaerobic
metabolism, cell motility and angiogenesis1. Overexpression of HIF-1α, a subunit of the HIF
complex, has been linked to metastasis of tumor cells, and resistance to radio and chemotherapy.
Because of this, HIF-1 has become an important therapeutic target for the inhibition of tumor
growth by small molecules. It is our goal to design and synthesize novel small-molecules that
disrupts HIF pathway mainly by targeting the HIF-1α subunit to prevent it from binding with the
HIF-1β subunit that makes the HIF heterodimer and initiate its biochemical activity as a
transcription factor that promote tumor cell growth. Mechanistic studies shows that these novel
inhibitors do not primarily alter HIF-1 levels rather, they interfere with the HIF complex
formation1. An initial HRE-alkaline phosphatase assay screening was done to find a lead
compound.
A compound (KCN-1) with an IC50 of 0.4µM was
tested and was found to be very potent in
decreasing tumor size. Optimization of the said
compound was subsequently done by dividing the
compound into 4 parts (cores) and analogues have
been made; the best compound made to date has
an IC50 of 0.25µM.

Figure 1 Molecular Structure of KCN-1
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